Skip to main content
Premium Trial:

Request an Annual Quote

Calimmune Initiates Phase I/II Trial of HIV Drug

Premium

Calimmune has become the latest RNAi drug developer to move into the clinic, recently initiating a phase I/II trial of its HIV therapy Cal-1.

The therapy is based on the work of UCLA AIDS Center and California Institute of Technology researchers, who discovered that the chemokine receptor CCR5 was used by the virus to infect cells.

With the approach, patients’ T cells and stem cells are isolated from peripheral blood, then treated with the HIV-1 fusion inhibitor C46, as well as a self-inactivating lentiviral vector encoding short hairpin RNAs against CCR5. The cells are then re-infused, with the treated T cells providing immediate protection against the virus and the stem cells offering long-term protection.

The clinical study is expected to enroll 12 patients, who will be divided into three cohorts. The first group will receive Cal-1 without any preconditioning with busulfan, a chemotherapeutic used during bone marrow transplantation procedures.

The second and third cohorts will receive either one or two initial doses of busulfan prior to Cal-1 treatment.

The phase I/II trial is slated to wrap up in mid-2015.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.